biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by TechnicalBuyon Aug 20, 2013 4:18pm

338 Views

Post# 21684499

RE:RE:to-BBB

Hi Sniper,

to-BBB was discussed to some extent on this board roughly 2 years ago. to-BBB is only able to deliver small molecules across the bbb. For that reason we deamed Bioasis' transcend technology to be superior. Small molecule vs large molecule delivery option is a big deal because most drugs are big molecules. There is quite a bit of literature on this on the net if you wish to explore further.

TB

Bullboard Posts

Canadian artificial intelligence ETFs